A Phase I, Open-label Study of the Absorption, Metabolism and Excretion of Defactinib (VS-6063-106) in Healthy Male Subjects
Latest Information Update: 29 May 2018
At a glance
- Drugs Defactinib (Primary)
- Indications Breast cancer; Cancer; Fallopian tube cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Verastem; Verastem Oncology
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 29 Sep 2016 New trial record